Serum Uric Acid Levels and Gouty Tophi Development

Relationship Between Serum Uric Acid and Tophi Formation

Higher serum uric acid levels correlate with increased risk of gout progression, including the development of tophi 1, 2
Markedly elevated serum uric acid concentrations (>9 mg/dL) are specifically identified in guidelines as indicating higher likelihood of gout progression and tophi development 1, 2
The American College of Rheumatology recommends that patients with serum uric acid levels above 9 mg/dL should be considered for urate-lowering therapy even after their first gout flare 1, 2

Patients with serum uric acid >9 mg/dL are at such high risk that guidelines recommend initiating urate-lowering therapy even after the first gout flare, which is not recommended for patients with lower uric acid levels 1, 2
Only about 20% of patients with asymptomatic hyperuricemia with serum uric acid concentrations >9 mg/dL develop gout within 5 years, but those who do are at high risk for tophi 2
Chronic kidney disease (stage ≥3) is also associated with higher likelihood of gout progression and development of clinical tophi, independent of uric acid level 1, 2

The presence of tophi is a strong indication for urate-lowering therapy, with a goal of complete resolution 4, 5

The treatment target for patients with gout is serum uric acid below 6 mg/dL to prevent crystal formation and promote dissolution of existing crystals 4
For patients with tophi, an even lower target of below 5 mg/dL is recommended to accelerate crystal dissolution and tophi resolution 4, 2

While serum uric acid levels do not confirm or exclude gout, levels >9 mg/dL represent a significant risk factor for tophi development 3, 6
Patients with visible tophi should always receive urate-lowering therapy, regardless of flare frequency 1, 5
Patients with asymptomatic hyperuricemia generally do not require treatment, even with elevated uric acid, unless they have had a gout flare or have developed tophi 2, 7